SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%–1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2-i improves the metabolic profile in patients with diabetes increasing glycosuria by inhibiting glucose reuptake in the renal proximal tubule. As a result, they induce a reduction of both arterial pressure and body weight, demonstrating impressive cardio- and nephro-protective effects [59].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 10×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundMethodResultInfluentialAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 5×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundInfluentialOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 14×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundMethodResultInfluential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 10×
“Results of DECLARE-TIMI, nevertheless, did not confirm a higher cancer risk with Dapa [69].”
BackgroundMethodResultInfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Administration of Cana led to the reduction of end-stage renal disease, doubling of the serum creatinine level, or death from renal or CV causes [85].”
Background
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
Henning, R. J. (2021) · Europe PMC (PubMed Central) · Cited by 327
Chen, S., Lv, L., Liu, B., & Tang, R. (2020) · Cell Proliferation · doi:10.1111/cpr.12763 · Cited by 158
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)
Takada, I., & Makishima, M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1703952 · Cited by 155
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
Butler, J., Usman, M. S., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G., Stewart Coats, A. J., & Anker, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13169 · Cited by 138
“Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a new foundational therapy in patients with heart failure (HF) and reduced ejection fraction (HFrEF).(1)”
BackgroundGlucose transporters in pancreatic islets
Berger, C., & Zdzieblo, D. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02383-4 · Cited by 153
Ravindran, S., & Munusamy, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30621 · Cited by 109
“cose, such that virtually no glucose is excreted in urine (Nespoux & Vallon, 2018; Tentolouris et al., 2019).”
BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival
Luo, J., HENDRYX, M. S., & Dong, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02177-2 · Cited by 87
“Four SGLT2 inhibitors, canagliflozin, dapagliflozin, empagliflozin and ertugliflozin, have been approved by the Food and Drug Administration (FDA), beginning with canagliflozin in March 2013 [8, 9].”
BackgroundDawwas, G. K., Smith, S. M., & Park, H. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13477 · Cited by 76
Elendu, C., Okah, M. J., Fiemotongha, K. J. D., Boluwatife, A. I., Bassey, B. N., Omeludike, E., & Obidigbo, B. T. (2023) · Medicine · doi:10.1097/md.0000000000035397 · Cited by 93
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 83
“Both metformin and gliflozins have been shown to reduce hyperglycemia and HbA1c and are being approved for the treatment of T2DM [186,187].”
BackgroundLing, A. W.-C., Chan, C.-C., Chen, S., Kao, Y., Huang, C.-Y., Chan, Y., & Chu, P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01162-w · Cited by 80
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
Mohan, M., Dihoum, A., Mordi, I. R., Choy, A. M., Rena, G., & Lang, C. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.746382 · Cited by 78
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Li, N., & Zhou, H. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s269514 · Cited by 73
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
HENDRYX, M. S., Dong, Y., Ndeke, J. M., & Luo, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274519 · Cited by 68
“Four SGLT2 inhibitors are now commercially available in the US including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin [13].”
BackgroundSGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 79
“73 m2, and renal replacement therapy and death from renal cause [12].”
BackgroundMehta, P. B., Robinson, A., Burkhardt, D., & Rushakoff, R. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.006 · Cited by 64
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
Radlinger, B., Ress, C., Folie, S., Salzmann, K., Lechuga, A., Weiss, B., Salvenmoser, W., Graber, M., Hirsch, J., Holfeld, J., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05851-x · Cited by 66
“Sodium–glucose cotransporter 2 (SGLT2) inhibitors are now widely used for their specific beneficial effects in individuals with type 2 diabetes [5, 6].”
BackgroundKoliaki, C. C., Tentolouris, A., Eleftheriadou, I., Melidonis, A. J., Dimitriadis, G., & Tentolouris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072288 · Cited by 62
Self-citationType 2 diabetes and impaired physical function: a growing problem
Ahmad, E., Sargeant, J. A., Yates, T., Webb, D. R., & Davies, M. J. (2022) · Diabetology · doi:10.3390/diabetology3010003 · Cited by 52
New Insights into the Use of Empagliflozin—A Comprehensive Review
Forycka, J., Hajdys, J., Krzemińska, J., Wilczopolski, P., Wronka, M., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Biomedicines · doi:10.3390/biomedicines10123294 · Cited by 64
Katsiki, N., Dimitriadis, G., Hahalis, G. N., Παπάνας, Ν., Tentolouris, N., Triposkiadis, F. K., Tsimihodimos, V., Tsioufis, C. P., Mikhailidis, D. P., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.008 · Cited by 56
Self-citationRepurposing existing drugs for COVID-19: an endocrinology perspective
Cadegiani, F. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00626-0 · Cited by 48
The relationship between SGLT2 and systemic blood pressure regulation
Ahwin, P., & Martinez, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01723-6 · Cited by 49
“SGLT2i are a recent class of antidiabetic medication that cause glucosuria by inhibiting glucose absorption in the proximal tubule of the nephron [29, 30].”
BackgroundSGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 49
Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial
Daniele, A. J., Gregorietti, V., Costa, D., & López‐Fernández, T. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00260-y · Cited by 44
“In animal models of anthracycline cardiotoxicity, SGLT2i prevented the increase in cytokines, as well as the reduction in cardiomyocyte viability, the increase in cardiomyocyte apoptosis, and myocardial fibrosis [8, 9].”
BackgroundExploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
Fernández‐Fernández, B., D’Marco, L., Górriz, J. L., Jacobs-Cachá, C., Kanbay, M., Lima, S. L., Porrini, E., Sarafidis, P. A., Soler, M. J., & Ortíz, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072030 · Cited by 42
Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients
Schricker, S., Oberacker, T., Fritz, P., Ketteler, M., Alscher, M. D., & Schanz, M. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000520894 · Cited by 40
Saijo, Y., Okada, H., Hata, S., Nakajima, H., Kitagawa, N., Okamura, T., Osaka, T., Kitagawa, N., Majima, S., Senmaru, T., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226993 · Cited by 35
“Although the cardioprotective mechanisms of SGLT2is have not yet been fully explained, promising hypotheses include an improvement in ventricular loading conditions induced by the diuretic effects, the enhancement of cardiac metabolism, the inhibition of Na + /H + exchange, and so on [10].”
BackgroundShiju, R., Akhil, A., Thankachan, S., Tuomilehto, J. O., Arouj, M. A., & Bennakhi, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3846253 · Cited by 40
“Commonly available drugs under this class include dapagli fl ozin, cana-gli fl ozin, ipragli fl ozin, empagli fl ozin, and ertugli fl ozin [54, 61].”
BackgroundFournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
Chowdhury, T., Gousy, N., Bellamkonda, A., Dutta, J., Zaman, C. F., Zakia, U. B., Tasha, T., Dutta, P., Roy, P. D., Gomez, A. M., et al. (2022) · Cureus · doi:10.7759/cureus.27773 · Cited by 46
“SGLT-1 is found in enterocytes, kidney epithelial cells, lungs, and cardiac cells that control the transport of glucose and galactose, whereas SGLT-2 is mainly located in proximal renal tubular cells, pancreatic cells, and the cerebellum [7,8].”
BackgroundHanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“A previous history of genital infections also increases the chance of developing an infection [64].”
Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 37
“Additional beneficial cardiometabolic effects may include the promotion of ketogenesis and possibly anti-inflammatory effects [48].”
El-Sayed, N., Mostafa, Y. M., Abogresha, N. M., Ahmed, A. A. M., Mahmoud, I. Z., & El-Sayed, N. M. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109617 · Cited by 33
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F. (2025) · Biomedicines · doi:10.3390/biomedicines13030608 · Cited by 39
“Initially introduced as antihyperglycemic drugs [28], SGLT2i have demonstrated significant cardiovascular benefits, particularly in the setting of chronic stable HF [29].”
SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review
Confederat, L. G., Dragostin, O.-M., & Condurache, M.-I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061960 · Cited by 38
“…glycated hemoglobin values (HbA1c), fasting plasma glucose and postprandial glucose levels in different trials that studied the effects on glycemic control in treatment-naive patients or when added to metformin, sulfonylureas, thiazolidinediones, DPP inhibitors, GLP1-RA or basal insulin [9].”
InfluentialRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Nanomedicines based on trace elements for intervention of diabetes mellitus
Ruan, S., Guo, X., Ren, Y., Cao, G., Xing, H., & Zhang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115684 · Cited by 39
Huang, D., Ju, F., Du, L., Liu, T., Zuo, Y., Abbott, G. W., & Hu, Z. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000956 · Cited by 31
“Notably, accumulating evidence suggests that apart from strong cardiovascular benefits (Tentolouris et al., 2019; Sarzani et al., 2020), SGLT2 inhibitors may also protect other vital organs, for”
BackgroundKwak, S. H., Han, K. A., Kim, K., Yu, J. M., Kim, E.-S., Won, J. C., Kang, J. G., Chung, C. H., Oh, S., Choi, S. H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15046 · Cited by 34
“Daewoong Pharmaceutical Company, Grant/Award Number: Not applicable Conclusions: Monotherapy with enavogliflozin 0.3 mg improved glycaemic control in people with T2DM.”
BackgroundInfluentialThe Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
“This pro-ketogenic effect holds promising implications for cardiovascular events such as stroke and HF, as well as for retarding the progression of chronic diseases, such as atherosclerosis and CKD [14,15].”
BackgroundKumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Tharayil, S. P., & Shukla, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136233 · Cited by 33
“…incretin mimetics are other insulin sensitisers with even stronger impacts on comorbidities such as obesity and CVD. SGLT2-i exhibits cardiovascular and nephron-protective effects by blocking glucose reuptake in the renal proximal tubule, leading to reduced arterial pressure and body weight [187].”
Bhanushali, K. B., Asnani, H., Nair, A. V., Ganatra, S., & Dani, S. S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102664 · Cited by 28
Tienda-Vázquez, M. A., Melchor-Martínez, E. M., Elizondo‐Luévano, J. H., Parra‐Saldívar, R., Lara-Ortiz, J. S., Luna-Sosa, B., & Scheckhuber, C. Q. (2023) · Processes · doi:10.3390/pr11051299 · Cited by 29
Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors
Shin, H., Paik, J. M., Everett, B. M., DiCesare, E., ALIX, C., Glynn, R. J., Wexler, D. J., & Patorno, E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.7357 · Cited by 33
Munteanu, C., Rotariu, M., Turnea, M. A., Anghelescu, A., Albadi, I., Dogaru, G., Silişteanu, S. C., Ionescu, E. V., Firan, F. C., Ionescu, A. M., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44080233 · Cited by 28
SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Kanduri, S. R., Kovvuru, K. R., Hansrivijit, P., Thongprayoon, C., Vallabhajosyula, S., Pivovarova, A. I., Chewcharat, A., Garla, V. V., Medaura, J. A., & Cheungpasitporn, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092723 · Cited by 28
Attimarad, M., Venugopala, K. N., Nair, A. B., Sreeharsha, N., & Deb, P. K. (2022) · Separations · doi:10.3390/separations9020023 · Cited by 29
Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review
Mîndrescu, N. M., Guja, C., Jinga, V., Ispas, S., Curici, A., Twakor, A. N., & Stoian, A. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063540 · Cited by 25
“The improvement in glucose management is evidenced by a decrease in HbA1c levels ranging from 0.5% to 1% [97].”
BackgroundInfluentialHan, B. G., Lee, J. Y., Kim, M. R., Shin, H., Kim, J. S., Yang, J. W., & Kim, J. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235640 · Cited by 24
“Proposed pathophysiologic mechanisms of SGLT-2 inhibitors for cardioprotective effects are natriuretic effect, weight loss, reduced arterial stiffness, and improvement in ventricular loading conditions [37, 38].”
BackgroundMacalalad, M. A. B., & Gonzales, A. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1969282 · Cited by 27
“An increased risk of bone fractures and decreased bone mineral density have been linked to the use of canagliflozin, for which the FDA issued a relevant warning (Tentolouris et al., 2019).”
BackgroundNagre, K., Singh, N., Ghoshal, C., Tandon, G., Iquebal, M. A., Nain, T., Bana, R. S., & Meena, A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1228172 · Cited by 25
Vinci, M. C., Gambini, E., Bassetti, B., Genovese, S., & Pompilio, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113864 · Cited by 25
Lapham, K., Callegari, E., Cianfrogna, J. A., Lin, J., Niosi, M., Orozco, C. C., Sharma, R., & Goosen, T. C. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000171 · Cited by 24
Dasari, D., Bhat, A., Mangali, S., Ghatage, T., Lahane, G. P., Sriram, D., & Dhar, A. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00207 · Cited by 26
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 25
“systolic and diastolic blood pressures by 4-6 and 1-2 mmHg, respectively.(13,14) In addition, SGLT2 inhibitor treatment leads to significant weight loss of up to 5 kg,(15) with mean weight loss across trials of between 2.”
BackgroundPharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats
Pang, M., Jeon, S. Y., Choi, M., Jeon, J.-H., Ji, H., Choi, J., & Song, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061210 · Cited by 23
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 30
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C., Chen, C., & Yeh, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01789-5 · Cited by 26
“The four most widely used SGLT2i, canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, all bind to the SGLT2 protein with varying degrees of affinity [3].”
BackgroundLeón‐González, A. J., Jiménez‐Vacas, J. M., Fuentes-Fayos, A. C., Sarmento‐Cabral, A., Herrera-Martínez, A. D., Gahete, M. D., & Luque, R. M. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.002 · Cited by 24
Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
Wu, J., Liu, Y., Wei, X., Zhang, X., Ye, Y., Li, W., & Su, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.915455 · Cited by 24
Malínská, H., Hüttl, M., Marková, I., Miklánková, D., Hojná, S., Papoušek, F., Šilhavý, J., Mlejnek, P., Zicha, J., Hrdlička, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092066 · Cited by 22
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 25
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 23
Mendoza, V. L., Tumanan-Mendoza, B. A., & Punzalan, F. E. R. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13583 · Cited by 24
“Currently, there are several SGLT2 inhibitors, and one of them is dapagliflozin.(1,2) The Dapagliflozin Effect on Cardiovascular Events– Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial evaluated dapagliflozin compared with placebo among”
BackgroundNovel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Kuoni, S., Steiner, R., Saleh, L., Lehmann, R., Ochsenbein‐Kölble, N., & Simões‐Wüst, A. P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116177 · Cited by 21
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 22
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
“In another study dapagliflozin improved endothelial dysfunction through increase of brachial artery flow-mediated dilation and reactive hyperemia index [52].”
BackgroundInfluentialResearch Progress of Bioactive Peptides in Improving Type II Diabetes
Yu, J., Chen, G., Jin, Y., Zhang, M., & Wu, T. (2025) · Foods · doi:10.3390/foods14030340 · Cited by 21
Tanashat, M., Manasrah, A., & Abouzid, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03660-2 · Cited by 19
“In patients with HF, SGLT2i has become a new standard treat-ment [8].”
Borges, R. D. S., Conegundes, A. F., de Paula, L. H., dos Santos, R. L. C., Alves, S. N., Machado, R. A., Viana, I. B., & Silva, A. C. S. E. (2024) · Pediatric Diabetes · doi:10.1155/2024/6295345 · Cited by 23
The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Liu, J., Tian, J., Sodhi, K., & Shapiro, J. I. (2021) · The Journal of Membrane Biology · doi:10.1007/s00232-021-00192-z · Cited by 19
Hirai, H., Liang, X., Sun, Y., Zhang, Y., Zhang, J., Chen, Y. E., Mou, H., Zhao, Y., & Xu, J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.008 · Cited by 18
“In recent years, SGLT inhibitor drugs have gained extraordinary successes in treating diabetes and several diseases beyond diabetes.(11) We are interested to know if this class of drugs has any potential to bring benefits to CF lung disease.”
BackgroundAttimarad, M., Venugopala, K. N., Chohan, M. S., David, M., Molina, E. I. P., Sreeharsha, N., Nair, A. B., Tratrat, C., Altaysan, A. I., & Balgoname, A. A. (2022) · Molecules · doi:10.3390/molecules27103135 · Cited by 20
Hassan, H. A., Nageeb, M. M., Mohammed, H. O., Samy, W. M., Fawzy, A., Afifi, R., & Abbas, N. A. T. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116991 · Cited by 19
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Biomedical aspects of beta-glucan on glucose metabolism and its role on primary gene PIK3R1
Chakraborty, S., & Rajeswari, V. D. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105296 · Cited by 18
Menzies‐Gow, N. J., & Knowles, E. J. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13470 · Cited by 16
“…associated with diabetes meta-analyses of randomized clinical trials have demonstrated that all four SGLT2i available for use in people achieve similar outcomes with respect to glycaemic control with weight loss and without increasing hypoglycaemia as monother-apies (Tentolouris et al., 2019).”
Diabetes mellitus: interdisciplinary medical, surgical and psychological therapeutic approach
Socea, B., Silaghi, A. M., Rebegea, L. F., Bălan, D. G., Bălălău, C., Ţenea-Cojan, T. Ş., Mihai, D. A., & Păunică, I. (2023) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1445 · Cited by 18
Ali, Z., Rehman, W. U., Rasheed, L., Alzahrani, A. Y. A., Ali, N., Hussain, R., Emwas, A.-H. M., Jaremko, M., & Abdellattif, M. H. (2024) · ACS Omega · doi:10.1021/acsomega.3c05854 · Cited by 16
Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy
Zhu, T., Ye, Z., Song, J., Zhang, J., Zhao, Y., Xu, F., Wang, J., Huang, X. S., Gao, B., & Li, F. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02369-x · Cited by 18
“Previous studies have unveiled that Dapa has beneficial effects on DCM through multiple pathways [27].”
BackgroundStudi In Silico Senyawa Daun Salam Sebagai Antidiabetes Melalui Mekanisme Inhibitor SGLT-2
Amin, S., Muhtar, N. L. N., Sumardiawan, D. K., & Yulianingsih, T. S. Y. (2024) · Jurnal Ilmu Medis Indonesia · doi:10.35912/jimi.v4i1.4539 · Cited by 16
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Dashora, U. K., Sinha, S., Seidu, S., Patel, D., Beba, H., & Strain, W. D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01242-y · Cited by 18
“However, although glycaemic control with diabetes treatments such as metformin, thiazolidinediones (TZD), sulfonylureas (SU) and dipeptidyl peptidase inhibitors (DPP4is) has been associated with decreased risk of microvascular complications, a similar reduction has not been observed for macrovascular complications or…”
BackgroundNovel approaches to glycomimetic design: development of small molecular weight lectin antagonists
Damalanka, V. C., Maddirala, A. R., & Janetka, J. W. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1857721 · Cited by 17
SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response
Mateoc-Sirb, T., Dumitrascu, A. L., Flangea, C., Puscasiu, D. A., Vlad, T., Popescu, R., Marina, C. D. L. C., & Vlad, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146937 · Cited by 15
“Some studies have shown that SGLT2 inhibitors are able to reduce diastolic blood pressure (BP) but without affecting heart rate [125–129], with the most intense effect belonging to Canagliflozin [125].”
Marulkar, V. S., & Bhatia, N. M. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10007-3 · Cited by 15
“Thus, inhibition of SGLT2 and SGLT1 in the proximal tubule reverses the normal glucose reabsorption and fosters the glucose excretion in the urine, helping to maintain glucose levels in the blood (Tentolouris et al. 2019).”
Hosny, N. M., & Darwısh, I. A. (2025) · Talanta · doi:10.1016/j.talanta.2025.127790 · Cited by 15
New and emerging cardiovascular and antihypertensive drugs
Chrysant, S. G., & Chrysant, G. S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1810232 · Cited by 15
Attimarad, M., Venugopala, K. N., Nair, A. B., Sreeharsha, N., Molina, E. I. P., Kotnal, R. B., Tratrat, C., Altaysan, A. I., Balgoname, A. A., & Deb, P. K. (2022) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2022.121303 · Cited by 15
Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview
Guo, Z., & Priefer, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102239 · Cited by 17
Mukherjee, P., Sanyal, S., Chadha, S., & Mukherjee, S. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303266512231103075551 · Cited by 19
Effect of empagliflozin on weight in patients with prediabetes and diabetes
Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh‐Tahami, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83820-7 · Cited by 14
“8–11 , and achieving greater weight loss necessitates long-term administration 12–15 .”
Metadata
- Authors
- Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-08-17
- Volume
- 16
- Issue
- 16
- Pages
- 2965
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6720282
- OpenAlex
- W2967960051
- Cited by
- 300
- References
- 183
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 55 · 2023: 54 · 2022: 54 · 2021: 40 · 2020: 26 · 2019: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, cardioprotection, renal protection, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glycosuria, HbA1c, arterial stiffness, endothelial function, Na+/H+ exchange, myocardial fibrosis, adverse events, lower limb amputation, acute kidney injury, cardiovascular risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Cardiotonic Agents, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.